Thus, Pustzai et al. have reported the results of a sub-cohort of I-SPY2 study, at the AACR 2020 meeting, in which 73 HER2-negative BC patients candidate to pre-operative chemotherapy received durvalumab (an anti-PD-L1 monoclonal antibody) 1500 mg IV Q4W for 3 cycles, with low-dose olaparib 100 mg PO BID from weeks 1 to 11, in combination with weekly paclitaxel (80 mg/m2) × 12, followed by AC × 4, as neoadjuvant chemotherapy. The gene discussed is ERBB2; the disease is breast cancer.